GABAA Receptor Ligands Often Interact with Binding Sites in the Transmembrane Domain and in the Extracellular Domain—Can the Promiscuity Code Be Cracked?

Total Page:16

File Type:pdf, Size:1020Kb

GABAA Receptor Ligands Often Interact with Binding Sites in the Transmembrane Domain and in the Extracellular Domain—Can the Promiscuity Code Be Cracked? International Journal of Molecular Sciences Article GABAA Receptor Ligands Often Interact with Binding Sites in the Transmembrane Domain and in the Extracellular Domain—Can the Promiscuity Code Be Cracked? Maria Teresa Iorio 1, Florian Daniel Vogel 2, Filip Koniuszewski 2, Petra Scholze 3 , Sabah Rehman 2, Xenia Simeone 2, Michael Schnürch 1, Marko D. Mihovilovic 1 and Margot Ernst 2,* 1 Institute of Applied Synthetic Chemistry, TU Wien, Getreidemarkt 9/163-OC, 1060 Vienna, Austria; [email protected] (M.T.I.); [email protected] (M.S.); [email protected] (M.D.M.) 2 Department of Molecular Neurosciences, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090 Vienna, Austria; fl[email protected] (F.D.V.); fi[email protected] (F.K.); [email protected] (S.R.); [email protected] (X.S.) 3 Department of Pathobiology of the Nervous System, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, 1090 Vienna, Austria; [email protected] * Correspondence: [email protected]; Tel.: +43-1-40160-34065 Received: 29 November 2019; Accepted: 26 December 2019; Published: 3 January 2020 Abstract: Many allosteric binding sites that modulate gamma aminobutyric acid (GABA) effects have been described in heteropentameric GABA type A (GABAA) receptors, among them sites for benzodiazepines, pyrazoloquinolinones and etomidate. Diazepam not only binds at the high affinity extracellular “canonical” site, but also at sites in the transmembrane domain. Many ligands of the benzodiazepine binding site interact also with homologous sites in the extracellular domain, among them the pyrazoloquinolinones that exert modulation at extracellular α+/β sites. Additional − interaction of this chemotype with the sites for etomidate has also been described. We have recently described a new indole-based scaffold with pharmacophore features highly similar to pyrazoloquinolinones as a novel class of GABAA receptor modulators. Contrary to what the pharmacophore overlap suggests, the ligand presented here behaves very differently from the identically substituted pyrazoloquinolinone. Structural evidence demonstrates that small changes in pharmacophore features can induce radical changes in ligand binding properties. Analysis of published data reveals that many chemotypes display a strong tendency to interact promiscuously with binding sites in the transmembrane domain and others in the extracellular domain of the same receptor. Further structural investigations of this phenomenon should enable a more targeted path to less promiscuous ligands, potentially reducing side effect liabilities. Keywords: receptors; GABAA; benzodiazepines (BZ); binding sites; etomidate 1. Introduction GABAA receptors are pentameric anion channels heavily expressed in the mammalian central nervous system. They are formed of five homologous subunits, encoded by 19 different genes. Despite the significant subtype heterogeneity, it is commonly accepted that the majority of receptors is formed of two α and β subunits and a single γ subunit. The subunits form a pentameric GABA gated ion pore, with subunit interfaces formed by a principal (or +) and a complementary (or ) face of each subunit as − Int. J. Mol. Sci. 2020, 21, 334; doi:10.3390/ijms21010334 www.mdpi.com/journal/ijms Int.Int. J. J. Mol. Mol. Sci. Sci. 20202020, ,2121, ,334 334 2 2of of 20 20 of each subunit as depicted in Figure 1. Treatments of epilepsy, anxiety states and sleep disorders, as welldepicted as anesthetics, in Figure1 .target Treatments GABA ofA receptors epilepsy, anxiety[1,2]. Among states andthese sleep drugs, disorders, benzodiazepines as well as anesthetics,are widely prescribedtarget GABA andA receptorsare known [1 to,2 ].exert Among their these effects drugs, via a benzodiazepinesbinding site on the are extracellular widely prescribed domain and of the are receptor.known to Specifically, exert their e fftheects binding via a binding site of site benzodiazepines on the extracellular is situated domain at of the the extracellular receptor. Specifically, domain the binding site of benzodiazepines is situated at the extracellular domain (ECD)- interface α+/γ (ECD)- interface α+/γ− (site 1, Figure 1) and homologous with the GABA binding site at the ECD-− (site 1, Figure1) and homologous with the GABA binding site at the ECD- β+/α interface [3,4]. β+/α− interface [3,4]. − BenzodiazepinesBenzodiazepines interact interact additionally additionally with with another another low low affinity affinity binding binding site site within within the the transmembranetransmembrane domain domain (TMD), (TMD), at at the the TMD-interface β+/+/α−α (site(site 3) 3) [5]. [5]. This This binding binding site site is is chiefly chiefly − knownknown as as the the site site of of action action for for the the clinically clinically used used drug drug etomidate, etomidate, an andd also also one one of of the the interaction interaction sites sites forfor propofol propofol [6,7]. [6,7]. BesidesBesides the the clinically clinically relevant relevant drugs, drugs, a a wide wide range range of of compounds compounds have have been been identified identified as as modulatorsmodulators of of the the GABA GABAAA receptorsreceptors [1,8–10]. [1,8–10]. FigureFigure 1. (a(a) )Schematic Schematic rendering rendering of of a a GABAA receptor.receptor. The The extracellular extracellular domain domain (ECD) (ECD) and and transmembranetransmembrane domain domain (TMD) (TMD) contai containn various various binding binding sites sites [11]. [11]. The The binding binding sites sites studied studied in in this this workwork are atat interfacesinterfaces formed formed by by a a principal principal (+ (+)) subunit subunit face face and and a complementary a complementary ( ) subunit(−) subunit face. face. The − Theshape shape resembles resembles vaguely vaguely a space a fillingspace renderingfilling rendering of the protein’s of the ECDprotein’s and TMD,ECD whileand TMD, intracellular while intracellulardomain (ICD) domain shape is(ICD) a purely shape schematic is a purely rendering schematic based rendering on more based remote on homologues.more remote homologues. (b) Schematic (planesb) Schematic through planes the ECDthrough (top) the and ECD TMD (top) (bottom) and TMD of (bottom) a canonical of a canonicalαβγ receptor, αβγ receptor, the GABA the sites GABA are indicated as dark grey ellipses. Site 1 (blue), the high affinity benzodiazepine site, is at the ECD– α+/γ sites are indicated as dark grey ellipses. Site 1 (blue), the high affinity benzodiazepine site, is at the− ECD–interface; α+/γ− site interface; 2 (blue), site which 2 (blue), confers which modulatory confers emoduffectslatory of pyrazoloquinolinone effects of pyrazoloquinolinone ligands is at the ligands ECD– α+/β interface, and site 3 (orange), the etomidate site [7] occurs twice and is located at the TMD– is at the− ECD– α+/β− interface, and site 3 (orange), the etomidate site [7] occurs twice and is located at β+/α interfaces below the GABA binding sites. the TMD–− β+/α− interfaces below the GABA binding sites. InIn a a previous previous work, work, we we identified identified a a series series of of indole indole derivatives, derivatives, sharing sharing pharmacophore pharmacophore features features with pyrazoloquinolinones (PQs), as GABA modulators (Figure2a) [ 12]. PQs are known to bind with with pyrazoloquinolinones (PQs), as GABAA A modulators (Figure 2a) [12]. PQs are known to bind withhigh high affinity affinity at the at BZthe siteBZ site (site (site 1) and1) and to to modulate modulate the the receptors receptors via via the the interactioninteraction withwith a second second binding site of the ECD, at the interface between α+ and β (site 2) [13]. An interaction of PQs with binding site of the ECD, at the interface between α+ and β−− (site 2) [13]. An interaction of PQs with sitesite 3 3 has has also also been been reported reported [14] [14] For For this this study, study, we selected the most efficacious efficacious compound of of the the previouslypreviously published library, MTI163 (Figure2 2).). Int. J. Mol. Sci. 2020, 21, 334 3 of 20 Int. J. Mol. Sci. 2020, 21, 334 3 of 20 FigureFigure 2. (a 2.) Structure(a) Structure of MTI163; of MTI163; (b) structure(b) structure of DCBS192; of DCBS192; (c) pharmacophores (c) pharmacophores of indole of indole derivatives derivatives (left)(left) and and of PQs of PQs (right); (right); (d) superposition(d) superposition of pharmacophores of pharmacophores of PQ of andPQ and indole indole derivatives. derivatives. Panels Panels c c andand d depict d depict the pharmacophoresthe pharmacophores already already discussed discussed in [12 in]. [12]. The high pharmacophoric overlap of the indole derivatives in comparison with the PQs (Figure2c,d) The high pharmacophoric overlap of the indole derivatives in comparison with the PQs (Figure suggests similar binding behavior. We therefore considered the three possible binding sites as object 2c,d) suggests similar binding behavior. We therefore considered the three possible binding sites as of our studies: site 1 (ECD- α+/γ ) site 2 (ECD- α+/β ), and site 3 (TMD- β+/α ). To investigate object of our studies: site 1 (ECD-− α+/γ−) site 2 (ECD-− α+/β−), and site 3 (TMD- −β+/α−). To investigate the putative binding and mechanism of action of the new scaffold at these three sites, we performed the putative binding and mechanism of action of the new scaffold at these three sites, we performed functional and mutational studies, as well as radioligand displacement assays. Computational docking functional and mutational studies, as well as radioligand displacement assays. Computational studies complement the experimental findings in the context of the recently published cryo EM docking studies complement the experimental findings in the context of the recently published cryo structure with the PDB identifier 6HUP [4], which features diazepam in binding sites 1 and 3. EM structure with the PDB identifier 6HUP [4], which features diazepam in binding sites 1 and 3. 2. Results 2. Results 2.1. Chemistry 2.1. Chemistry The indole derivative MTI163 was synthesized as previously described [12].
Recommended publications
  • Efficient Synthesis of Pyrazolopyridines Containing a Chromane Backbone Through Domino Reaction
    Efficient synthesis of pyrazolopyridines containing a chromane backbone through domino reaction Razieh Navari1, Saeed Balalaie*1,2, Saber Mehrparvar1, Fatemeh Darvish1, Frank Rominger3, Fatima Hamdan1 and Sattar Mirzaie1 Full Research Paper Open Access Address: Beilstein J. Org. Chem. 2019, 15, 874–880. 1Peptide Chemistry Research Center, K. N. Toosi University of doi:10.3762/bjoc.15.85 Technology, P. O. Box 15875-4416, Tehran, Iran, Tel: +98-21-23064226, Fax: +98-21-22889403, 2Medical Biology Received: 07 February 2019 Research Center, Kermanshah University of Medical Sciences, Accepted: 29 March 2019 Kermanshah, Iran and 3Organisch-Chemisches Institut der Published: 11 April 2019 Universitaet Heidelberg, Im Neuenheimer Feld 270, D-69120 Heidelberg, Germany Associate Editor: T. J. J. Müller Email: © 2019 Navari et al.; licensee Beilstein-Institut. Saeed Balalaie* - [email protected] License and terms: see end of document. * Corresponding author Keywords: chromane; domino reaction; fused heterocyclic skeletons; pyrazolopyridines Abstract An efficient approach for the synthesis of pyrazolopyridines containing the aminochromane motif through a base-catalyzed cycliza- tion reaction is reported. The synthesis was carried out through a three-component reaction of (arylhydrazono)methyl-4H-chromen- 4-one, malononitrile, primary amines in the presence of Et3N at room temperature. However, carrying out the reaction under the same conditions without base led to a fused chromanyl-cyanopyridine. High selectivity, high atom economy, and good to high yields in addition to mild reaction conditions are the advantages of this approach. Introduction The synthesis of new fused heterocyclic backbones has always Chromone derivatives have been found to exhibit a broad range been a major challenge in the field of organic synthesis [1-3].
    [Show full text]
  • Poisoning – Investigative and Management Protocols
    UNIT-1 Management of Common Clinical Poisoning Dr. Pallav Shekhar Asstt. Professor Veterinary Medicine Suspection Common Symptoms exhibited by large no. of animals at a time. ➢ Sudden death ➢ Salivation ➢ Vomition ➢ Neurological signs ➢ Presence of mouldy feeds ➢ Presence of house hold waste and medicaments ➢ Sewage water contamination ➢ Presence of dead rat or rat wait ➢ Spray of insecticides, weedicides. ➢ Use of paint Principal of treatment Prevention of further exposure Alkalis are more dangerous than acids. Acids form insoluble acid proteinates and hence its effect is partially self limiting Alkalis form alkali proteinates along with soaps which will penetrate rapidly into tissues. Inhaled poisons can be eliminated by providing assisted ventilation. Topical applied toxicant can be removed by washing with plenty of water and soap. Skin contact can be eliminated by washing with plenty of water and soap if the poison is water soluble and with organic solvents like Benzene, alcohol if they are fat soluble Conti…. Clipping of hair or wool may be necessary Emesis is of value in dogs, cats and pigs if done within few hours of ingestion. Emesis is contraindicated when ▪ The swallowing reflex is absent ▪ Animal is convulsive ▪ Corrosive agent or volatile hydrocarbons or petroleum product ingested Conti…. Emetics: a) Oral: I. Syrup of ipecac; 10-20ml in dogs II. Hydrogen peroxide: 2ml/kg b) Parenteral: Apomorphine can be used in dogs at dosage of 0.05-0.1mg/kg Conti… Gastric lavage: This is done in mono-gastric animals and 10ml lavage fluid/kg body weight should be given. Potassium permanganate solution This is done with Endotracheal tube and stomach tube Conti… Insertion of stomach tube in cattle for gastric lavage Conti.
    [Show full text]
  • Valerenic Acid Potentiates and Inhibits GABAA Receptors: Molecular Mechanism and Subunit Specificity
    ARTICLE IN PRESS + MODEL Neuropharmacology xx (2007) 1e10 www.elsevier.com/locate/neuropharm Valerenic acid potentiates and inhibits GABAA receptors: Molecular mechanism and subunit specificity S. Khom a, I. Baburin a, E. Timin a, A. Hohaus a, G. Trauner b, B. Kopp b, S. Hering a,* a Department of Pharmacology and Toxicology, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria b Department of Pharmacognosy, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria Received 8 December 2006; received in revised form 11 April 2007; accepted 30 April 2007 Abstract Valerian is a commonly used herbal medicinal product for the treatment of anxiety and insomnia. Here we report the stimulation of chloride currents through GABAA receptors (IGABA) by valerenic acid (VA), a constituent of Valerian. To analyse the molecular basis of VA action, we expressed GABAA receptors with 13 different subunit compositions in Xenopus oocytes and measured IGABA using the two-microelectrode voltage-clamp technique. We report a subtype-dependent stimulation of IGABA by VA. Only channels incorporating b2 or b3 subunits were stimulated by VA. Replacing b2/3 by b1 drastically reduced the sensitivity of the resulting GABAA channels. The stimulatory effect of VA on a1b2 receptors was substantially reduced by the point mutation b2N265S (known to inhibit loreclezole action). Mutating the corresponding residue of b1 (b1S290N) induced VA sensitivity in a1b1S290N comparable to a1b2 receptors. Modulation of IGABA was not significantly dependent on incorporation of a1, a2, a3 or a5 subunits. VA displayed a significantly lower efficiency on channels incorporating a4 subunits. IGABA modulation by VA was not g subunit dependent and not inhibited by flumazenil (1 mM).
    [Show full text]
  • Crystal Structure Analysis of Ethyl 6-(4-Methoxyphenyl)-1-Methyl-4-Methyl- Sulfanyl-3-Phenyl-1H-Pyrazolo[3,4-B]Pyridine-5-Carboxylate
    research communications Crystal structure analysis of ethyl 6-(4-methoxy- phenyl)-1-methyl-4-methylsulfanyl-3-phenyl-1H- pyrazolo[3,4-b]pyridine-5-carboxylate ISSN 2056-9890 H. Surya Prakash Rao,a,b* Ramalingam Gunasundarib and Jayaraman Muthukumaranc‡ Received 4 June 2020 aDepartment of Chemistry and Biochemistry, School of Basic Sciences and Research, Sharda University, Greater Noida Accepted 30 June 2020 201306, India, bDepartment of Chemistry, Pondicherry University, Puducherry 605 014, India, and cDepartment of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida 201306, India. *Correspon- dence e-mail: [email protected] Edited by D. Chopra, Indian Institute of Science Education and Research Bhopal, India In the title compound, C24H23N3O3S, the dihedral angle between the fused ‡ Additional correspondence author, e-mail: pyrazole and pyridine rings is 1.76 (7) . The benzene and methoxy phenyl rings [email protected]. make dihedral angles of 44.8 (5) and 63.86 (5) , respectively, with the pyrazolo[3,4-b] pyridine moiety. An intramolecular short SÁÁÁO contact Keywords: crystal structure; pyrazolopyridine; [3.215 (2) A˚ ] is observed. The crystal packing features C—HÁÁÁ interactions. pyrazolo[3,4-b]pyridine; C—HÁÁÁ interactions. CCDC reference: 2005976 Supporting information: this article has 1. Chemical context supporting information at journals.iucr.org/e Pyrazolopyridines, in which a group of three nitrogen atoms is incorporated into a bicyclic heterocycle, are privileged medicinal scaffolds, often utilized in drug design and discovery regimes (Kumar et al., 2019). Owing to the possibilities of the easy synthesis of a literally unlimited number of a combina- torial library of small organic molecules with a pyrazolo- pyridine scaffold, there has been enormous interest in these molecules among medicinal chemists (Kumar et al.
    [Show full text]
  • GABA Receptors
    D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43.
    [Show full text]
  • Dynamic Regulation of the GABAA Receptor Function by Redox Mechanisms S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2016/07/20/mol.116.105205.DC1 1521-0111/90/3/326–333$25.00 http://dx.doi.org/10.1124/mol.116.105205 MOLECULAR PHARMACOLOGY Mol Pharmacol 90:326–333, September 2016 Copyright ª 2016 by The American Society for Pharmacology and Experimental Therapeutics MINIREVIEW—A LATIN AMERICAN PERSPECTIVE ON ION CHANNELS Dynamic Regulation of the GABAA Receptor Function by Redox Mechanisms s Daniel J. Calvo and Andrea N. Beltrán González Laboratorio de Neurobiología Celular y Molecular, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular Downloaded from ¨Dr. Héctor N. Torres¨ (INGEBI), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Argentina (D.J.C., A.N.B.G.) Received May 15, 2016; accepted July 14, 2016 ABSTRACT molpharm.aspetjournals.org Oxidizing and reducing agents, which are currently involved normally present in neurons and glia or are endogenously in cell metabolism and signaling pathways, can regulate fast generated in these cells under physiologic states or during inhibitory neurotransmission mediated by GABA receptors in the oxidative stress (e.g., hydrogen peroxide, superoxide and hy- nervous system. A number of in vitro studies have shown that droxyl radicals, nitric oxide, ascorbic acid, and glutathione), diverse redox compounds, including redox metabolites and induce potentiating or inhibiting actions on different native and reactive oxygen and nitrogen species, modulate phasic and recombinant GABAA receptor subtypes. Based on these results, it tonic responses mediated by neuronal GABAA receptors through is thought that redox signaling might represent a homeostatic both presynaptic and postsynaptic mechanisms.
    [Show full text]
  • Anxiety Disorders and GABA Neurotransmission: a Disturbance of Modulation
    Journal name: Neuropsychiatric Disease and Treatment Article Designation: REVIEW Year: 2015 Volume: 11 Neuropsychiatric Disease and Treatment Dovepress Running head verso: Nuss Running head recto: Anxiety and modulation open access to scientific and medical research DOI: http://dx.doi.org/10.2147/NDT.S58841 Open Access Full Text Article REVIEW Anxiety disorders and GABA neurotransmission: a disturbance of modulation Philippe Nuss1,2 Abstract: Lines of evidence coming from many branches of neuroscience indicate that anxiety 1Department of Psychiatry, Hôpital St disorders arise from a dysfunction in the modulation of brain circuits which regulate emotional Antoine, AP-HP, 2UMR 7203, INSERM responses to potentially threatening stimuli. The concept of anxiety disorders as a disturbance ERL 1057 – Bioactive Molecules of emotional response regulation is a useful one as it allows anxiety to be explained in terms Laboratory, Pierre and Marie Curie University, Paris, France of a more general model of aberrant salience and also because it identifies avenues for devel- oping psychological, behavioral, and pharmacological strategies for the treatment of anxiety disorder. These circuits involve bottom-up activity from the amygdala, indicating the presence of potentially threatening stimuli, and top-down control mechanisms originating in the prefron- tal cortex, signaling the emotional salience of stimuli. Understanding the factors that control cortical mechanisms may open the way to identification of more effective cognitive behavioral strategies for managing anxiety disorders. The brain circuits in the amygdala are thought to For personal use only. comprise inhibitory networks of γ-aminobutyric acid-ergic (GABAergic) interneurons and this neurotransmitter thus plays a key role in the modulation of anxiety responses both in the normal and pathological state.
    [Show full text]
  • Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors
    International Journal of Molecular Sciences Article Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors Hana Kubová 1,* , Zde ˇnkaBendová 2,3 , Simona Moravcová 2,3 , Dominika Paˇcesová 2,3, Luisa Rocha 4 and Pavel Mareš 1 1 Institute of Physiology, Academy of Sciences of the Czech Republic, 14220 Prague, Czech Republic; [email protected] 2 Faculty of Science, Charles University, 12800 Prague, Czech Republic; [email protected] (Z.B.); [email protected] (S.M.); [email protected] (D.P.) 3 National Institute of Mental Health, 25067 Klecany, Czech Republic 4 Pharmacobiology Department, Center of Research and Advanced Studies, Mexico City 14330, Mexico; [email protected] * Correspondence: [email protected]; Tel.: +420-2-4106-2565 Received: 31 March 2020; Accepted: 28 April 2020; Published: 30 April 2020 Abstract: Benzodiazepines (BZDs) are widely used in patients of all ages. Unlike adults, neonatal animals treated with BZDs exhibit a variety of behavioral deficits later in life; however, the mechanisms underlying these deficits are poorly understood. This study aims to examine whether administration of clonazepam (CZP; 1 mg/kg/day) in 7–11-day-old rats affects Gama aminobutyric acid (GABA)ergic receptors in both the short and long terms. Using RT-PCR and quantitative autoradiography, we examined the expression of the selected GABAA receptor subunits (α1, α2, α4, γ2, and δ) and the GABAB B2 subunit, and GABAA, benzodiazepine, and GABAB receptor binding 48 h, 1 week, and 2 months after treatment discontinuation. Within one week after CZP cessation, the expression of the α2 subunit was upregulated, whereas that of the δ subunit was downregulated in both the hippocampus and cortex.
    [Show full text]
  • Identification of Compounds That Rescue Otic and Myelination
    RESEARCH ARTICLE Identification of compounds that rescue otic and myelination defects in the zebrafish adgrg6 (gpr126) mutant Elvira Diamantopoulou1†, Sarah Baxendale1†, Antonio de la Vega de Leo´ n2, Anzar Asad1, Celia J Holdsworth1, Leila Abbas1, Valerie J Gillet2, Giselle R Wiggin3, Tanya T Whitfield1* 1Bateson Centre and Department of Biomedical Science, University of Sheffield, Sheffield, United Kingdom; 2Information School, University of Sheffield, Sheffield, United Kingdom; 3Sosei Heptares, Cambridge, United Kingdom Abstract Adgrg6 (Gpr126) is an adhesion class G protein-coupled receptor with a conserved role in myelination of the peripheral nervous system. In the zebrafish, mutation of adgrg6 also results in defects in the inner ear: otic tissue fails to down-regulate versican gene expression and morphogenesis is disrupted. We have designed a whole-animal screen that tests for rescue of both up- and down-regulated gene expression in mutant embryos, together with analysis of weak and strong alleles. From a screen of 3120 structurally diverse compounds, we have identified 68 that reduce versican b expression in the adgrg6 mutant ear, 41 of which also restore myelin basic protein gene expression in Schwann cells of mutant embryos. Nineteen compounds unable to rescue a strong adgrg6 allele provide candidates for molecules that may interact directly with the Adgrg6 receptor. Our pipeline provides a powerful approach for identifying compounds that modulate GPCR activity, with potential impact for future drug design. DOI: https://doi.org/10.7554/eLife.44889.001 *For correspondence: [email protected] †These authors contributed Introduction equally to this work Adgrg6 (Gpr126) is an adhesion (B2) class G protein-coupled receptor (aGPCR) with conserved roles in myelination of the vertebrate peripheral nervous system (PNS) (reviewed in Langenhan et al., Competing interest: See 2016; Patra et al., 2014).
    [Show full text]
  • Automated Kappa Number Determination of Pulp
    Application Note YSI, a Xylem Brand • XA00077 Automated Kappa Number Determination of Pulp PULP & PAPER SERIES Introduction The Kappa number describes the Lignin content of pulp which gives information about the bleaching process of the pulp. The longer the pulp was cooked and bleached the lower the Kappa number is. For the determination of the Kappa number a sample weight adjusted to the expected result is chopped and inserted into a beaker, then 400 ml of water is added. The sample/water mixture is stirred for 10 minutes. Afterwards 50 ml of potassium permanganate (KMnO4, 0.02 mol/L) and 50 ml sulfuric acid (H2SO4, 2 mol/L) are added simultaneously. The mixture is stirred for another 10 minutes. The reaction is stopped by adding 10 ml potassium iodide (KI, 1mol/l). The excess of KMnO4 reacts with Iodide to Iodine, which is titrated with sodium thiosulfate (Na2S2O3, 0.2 mol/L). Chemical Equations: The weight is adjusted to a consumption of about 50% of the MnO4- . - + ➔ - Lignin + MnO4 + 4 H oxidised Lignin + MnO4 (excess) + MnO2 + 2 H2O The reaction is stopped by adding KI. - - + ➔ 2+ 2 MnO4 + 10 I + 16 H 2 Mn + 5 I2 + 8 H2O The formed Iodine is titrated with Na2S2O3. 2- ➔ - 2 S2O3 + I2 S4O6 + 2 I Calculation of the Kappa number: 1. Calculation of the consumed volume Va of KMnO4: 2. Calculation of a correction factor d, which corrects the consumption of permanganate depending on Va to a V1 – V2)c Va = consumption of 50%. 0.1 with d= 100.00093 (2Va – 50) In(10) • 0.00093 (2Va– 50)) V1 = Consumption of Na2S2O3 during blank titration = e V2 = Consumption of Na2S2O3 during sample titration c = Concentration of Na2S2O3 3.
    [Show full text]
  • Page 1 of 7 Analyst
    Analyst Accepted Manuscript This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication. Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available. You can find more information about Accepted Manuscripts in the Information for Authors. Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. www.rsc.org/analyst Page 1 of 7 Analyst 1 2 Analyst RSC Publishing 3 4 5 ARTICLE 6 7 8 9 Enhancing permanganate chemiluminescence 10 detection for the determination of glutathione and 11 Cite this: DOI: 10.1039/x0xx00000x 12 glutathione disulfide in biological matrices 13 14 a a a b 15 Zoe M. Smith, Jessica M. Terry, Neil W. Barnett, Laura J. Gray, Dean J. Received 00th January 2012, Wright c and Paul S. Francis a* 16 Accepted 00th January 2012 17 18 DOI: 10.1039/x0xx00000x Acidic potassium permanganate chemiluminescence enables direct post-column detection of 19 glutathione, but its application to assess the redox state of a wider range of biological fluids www.rsc.org/ 20 and tissues is limited by its sensitivity.
    [Show full text]
  • WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/072852 Al 21 May 2015 (21.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 36/84 (2006.01) A61K 31/5513 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/045 (2006.01) A61P 31/22 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/522 (2006.01) A61K 45/06 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/NL20 14/050780 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 13 November 2014 (13.1 1.2014) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 61/903,430 13 November 2013 (13. 11.2013) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: RJG DEVELOPMENTS B.V.
    [Show full text]